Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution (1995)
    Springer
    Annals of hematology 71 (1995), S. 227-234 
    Details
    ISSN: 1432-0584
    Keywords: Key words PBPC autografting ; Apheresis results ; Hematopoietic recovery
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  One hundred and nine patients suffering from various malignancies underwent 285 apheresis procedures for PBPC collection. A median of two leukaphereses (range: 2–5) resulted in median numbers of 4.6×108 MNC/kg, 14.1×104 CFU-GM/kg, and 6.0×106 CD34+ cells/kg. Preleukapheresis peripheral blood CD34+ cells correlated significantly with collected CD34+ cells/kg (r=0.94;p〈0.0001) and with CFU-GM/kg (r=0.52;p〈0.0001). A value 〉4×104 CD34+ cells/ml was highly predictive for a collection yield 〉2.5×106 CD34+ cells/kg harvested by a single leukapheresis. Sixty patients were evaluated for hematologic reconstitution and engrafted in a median time of 10 days for WBC 〉1.0×109/l (range: 7–21 days), 10 days for ANC 〉0.5×109/l (7–20) and 11 days for PLT 〉20×109/l (7–62). Reinfused CD34+ cells/kg correlated significantly with hematologic engraftment (r=0.44–0.52 and p〈0.006–0.001) as well as CFU-GM/kg (r=0.36–0.44 and p〈0.007–0.001). A progenitor cell dose 〉2.5×106 CD34+ cells/kg or 〉8.0×104 CFUGM/kg led to a significantly faster recovery for WBC, ANC, and PLT when compared with patients receiving 〈2.5×106 CD34+ cells/kg or 〈8.0×104 CFU-GM/kg. We conclude that rapid hematopoietic engraftment after high-dose therapy and PBPC reinfusion correlates well with a progenitor cell dose 〉2.5×106 CD34+ cells/kg or 〉8.0×104 CFU-GM/kg, and that above a preleukapheresis threshold of 4×104 CD34+ cells/ml a PBPC autograft containing 〉2.5×106 CD34+ cells/kg can be collected by a single leukapheresis. We suggest that patients recovering from myelosuppression should be monitored for CD34+ cells in serial blood samples to determine the course of circulating hematopoietic progenitor cells. This issue will help to define the optimal time point to start apheresis and to predict a PBPC autograft harvested by a single leukapheresis, which will lead to rapid and stable hematopoietic reconstitution following transplantation.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01744372
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    High-dose chemotherapy and reinfusion of haematopoietic stem cells advanced germ cell tumours with poor prognosis in 1996 (1997)
    Springer
    Der Urologe 36 (1997), S. 561-564 
    Details
    ISSN: 1433-0563
    Keywords: Key words Germ cell tumours • High dose chemotherapy (HDCT) • Risk factors • Stem cell separation • Stem cell reinfusion ; Schlüsselwörter Keimzelltumoren • Hochdosischemotherapie (HDCT) • Risikofaktoren • Stammzellseparation • Stammzellreinfusion
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Die Hochdosischemotherapie (HDCT) ist für Patienten mit prognostisch ungünstigen Keimzelltumoren eine vielversprechende Behandlungsform. Für den erstbehandelnden Urologen besteht die Schwierigkeit, Patientengruppen zu selektionieren, die für diese Therapie in Betracht kommen und profitieren können. Entsprechend sorgfältig müssen die Indikationen herausgearbeitet werden. Die Ausschlußkriterien beziehen sich vor allem auf beeinträchtigte Organreserven. Vor einer HDCT werden nach vorangegangenen konventionell dosierten Chemotherapiezyklen hämatopoetische Stammzellen mit G- oder GM-CSF-Unterstützung gewonnen. Für die HDCT werden Kombinationen von Carboplatin, Etoposid und Ifosfamid oder Cyclophosphamid eingesetzt. Hämatologische Überwachung und der Einsatz aller erforderlichen supportiven Maßnahmen sind unabdingbare Voraussetzungen, um Patienten nicht zu Schaden kommen zu lassen. Deshalb wird empfohlen, eine HDCT nur an geeigneten Zentren durchzuführen.
    Notes: Summary High-dose chemotherapy (HDCT) is a promising treatment for patients with germ cell tumours and a poor prognosis. The selection of patients who may profit from this intervention is challenging for the urologist, as the indication has to be carefully established. Exclusion criteria primarily concern impaired organ functions. Prior to HDCT haematopoietic stem cells are obtained after the administration of conventional-dose chemotherapy plus G- or GM-CSF stimulation. HDCT consists of a combination of carboplatin, etoposide and ifosfamide or cyclophosphamide. After HDCT, haematologic monitoring and maximal supportive care are essential. It is therefore recommended that HDCT only be administered at specialized centres.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s001200050138
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Salvagetherapie rezidivierter und refraktärer Hodentumoren (1998)
    Springer
    Der Onkologe 4 (1998), S. 541-546 
    Details
    ISSN: 1433-0415
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Die Therapie der Patienten, die auf eine eine cisplatinhaltige Primärtherapie nicht oder nur inkomplett ansprechen oder bei denen ein Rezidiv auftritt, besteht in der „Salvage”- Therapie, unabhängig davon, ob diese bei primär refraktären Patienten oder bei Patienten im ersten oder nachfolgenden Rezidiv eingesetzt wird. Heilungen sind selbst bei dieser prognostisch ungünstigeren Patientengruppe möglich, erfordern jedoch den vollen Einsatz interdisziplinärer onkologischer Maßnahmen. In den vergangenen Jahren wurden große Anstrengungen unternommen, die Ergebnisse der Salvagechemotherapie zu verbessern und neben der Einführung neuerer Substanzen wird zunehmend die Hochdosischemotherapie untersucht.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s007610050236
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients (1995)
    Springer
    Annals of hematology 71 (1995), S. 287-291 
    Details
    ISSN: 1432-0584
    Keywords: Key words Aspergillosis ; Amphotericin B ; Inhalation ; Neutropenia ; Prophylaxis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  To determine the value of aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis (IPA), we initiated a prospective randomized multicenter trial. The scheduled intent-to-treat interim analysis included 115 patients (30%) with prolonged neutropenia after chemotherapy for acute myeloid leukemia, acute lymphoblastic leukemia/high-grade non-Hodgkin's lymphoma, or solid tumors undergoing autologous stem cell transplantation. Sixty-five patients had been randomized to receive prophylactic aerosol amphotericin B inhalations at a dose of 10 mg twice daily (group A); for the remaining 50 patients no aerosol amphotericin B prophylaxis was used (group B). No serious side effects from amphotericin B inhalations occurred, but coughing (54%), bad taste (51%), and nausea (37%) caused early cessation of aerosol amphotericin B prophylaxis in 23% (15/65) of courses. In group A, the incidence of proven, probable, or possible IPA was 5% (3/65) as compared with 12% (6/50) in group B (p〉0.05). Microbiologically documented bacterial pneumonias were observed in 5/65 (8%) patients in group A and in 1/50 (2%) patients in group B (p〉0.05). Thus, no reduction in incidence of IPA from use of prophylactic aerosol amphotericin B inhalations was found in this interim analysis. As there were no serious side effects from aerosol amphotericin B prophylaxis, accrual in the study will continue for a total of 380 patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01697981
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution (1995)
    Springer
    Annals of hematology 71 (1995), S. 227-234 
    Details
    ISSN: 1432-0584
    Keywords: PBPC autografting ; Apheresis results ; Hematopoietic recovery
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract One hundred and nine patients suffering from various malignancies underwent 285 apheresis procedures for PBPC collection. A median of two leukaphereses (range: 2–5) resulted in median numbers of 4.6×108 MNC/kg, 14.1×104 CFU-GM/kg, and 6.0×106 CD34+ cells/kg. Preleukapheresis peripheral blood CD34+ cells correlated significantly with collected CD34+ cells/kg (r=0.94;p〈0.0001) and with CFU-GM/kg (r=0.52;p〈0.0001). A value 〉4×104 CD34+ cells/ml was highly predictive for a collection yield 〉2.5×106 CD34+ cells/kg harvested by a single leukapheresis. Sixty patients were evaluated for hematologic reconstitution and engrafted in a median time of 10 days for WBC 〉1.0×109/l (range: 7–21 days), 10 days for ANC 〉0.5×109/l (7–20) and 11 days for PLT 〉20×109/l (7–62). Reinfused CD34+ cells/kg correlated significantly with hematologic engraftment (r=0.44–0.52 andp〈0.006–0.001) as well as CFU-GM/ kg (r=0.36–0.44 andp〈0.007–0.001). A progenitor cell dose 〉2.5×106 CD34+ cells/kg or 〉8.0×104 CFU-GM/kg led to a significantly faster recovery for WBC, ANC, and PLT when compared with patients receiving 〈2.5×106 CD34+ cells/kg or 〈 8.0×104 CFU-GM/kg. We conclude that rapid hematopoietic engraftment after high-dose therapy and PBPC reinfusion correlates well with a progenitor cell dose 〉2.5×106 CD34+ cells/kg or 〉8.0×104 CFU-GM/kg, and that above a preleukapheresis threshold of 4×104 CD34+ cells/ml a PBPC autograft containing 〉2.5×106 CD34+ cells/kg can be collected by a single leukapheresis. We suggest that patients recovering from myelosuppression should be monitored for CD34+ cells in serial blood samples to determine the course of circulating hematopoietic progenitor cells. This issue will help to define the optimal time point to start apheresis and to predict a PBPC autograft harvested by a single leukapheresis, which will lead to rapid and stable hematopoietic reconstitution following transplantation.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01744372
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients (1995)
    Springer
    Annals of hematology 71 (1995), S. 287-291 
    Details
    ISSN: 1432-0584
    Keywords: Aspergillosis ; Amphotericin B Inhalation ; Neutropenia ; Prophylaxis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract To determine the value of aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis (IPA), we initiated a prospective randomized multicenter trial. The scheduled intent-to-treat interim analysis included 115 patients (30%) with prolonged neutropenia after chemotherapy for acute myeloid leukemia, acute lymphoblastic leukemia/high-grade non-Hodgkin's lymphoma, or solid tumors undergoing autologous stem cell transplantation. Sixty-five patients had been randomized to receive prophylactic aerosol amphotericin B inhalations at a dose of 10 mg twice daily (group A); for the remaining 50 patients no aerosol amphotericin B prophylaxis was used (group B). No serious side effects from amphotericin B inhalations occurred, but coughing (54%), bad taste (51%), and nausea (37%) caused early cessation of aerosol amphotericin B prophylaxis in 23% (15/65) of courses. In group A, the incidence of proven, probable, or possible IPA was 5% (3/65) as compared with 12% (6/50) in group B (p〉0.05). Microbiologically documented bacterial pneumonias were observed in 5/65 (8%) patients in group A and in 1/50 (2%) patients in group B (p〉0.05). Thus, no reduction in incidence of IPA from use of prophylactic aerosol amphotericin B inhalations was found in this interim analysis. As there were no serious side effects from aerosol amphotericin B prophylaxis, accrual in the study will continue for a total of 380 patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01697981
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    High-dose chemotherapy with autologous stem cell support in poor-risk germ cell tumors (1998)
    Springer
    Annals of hematology 76 (1998), S. 183-188 
    Details
    ISSN: 1432-0584
    Keywords: Key words Germ cell tumor ; High-dose chemotherapy ; Autologous stem cell transplantation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  High-dose chemotherapy (HDT) and stem cell transplantation is a newer treatment option widely applied in poor-risk germ cell tumor patients. Due to the increasing practical clinical experience and the availability of hematopoietic growth factors, this treatment approach has become a relatively safe procedure. Depending on the drugs used, the most prominent therapy-associated side effects are myelosuppression, infections, mucositis, moderate, mostly reversible neurotoxicity, and renal impairment. Because of their unique pharmacologic characteristics, carboplatin and etoposide have proved to be the most important drugs for HDT. It is not known whether the addition of ifosfamide or cyclophosphamide or other drugs to the combination of carboplatin and etoposide leads to superior results. It is not yet clear if HDT should already be instituted in first-line treatment of poor-risk patients, or later after relapse or incomplete response. Even if precise data on the therapeutic value of HDT are still missing because randomized trials are not yet ready for evaluation, there is good evidence for the effectiveness of HDT. The demonstration of remissions in cisplatin-refractory patients, the inversion of remission durations, and the induction of long-term freedom from disease in multiply relapsed patients who were deemed incurable with conventional-dose procedures argue in favor of HDT. Finally, the delineation of prognostic factors associated with a poor probability of survival after HDT contributes to the selection of patients who are likely to profit from HDT and those who should be spared from dose-intensive treatment.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002770050386
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Abstracts of papers and posters advanced activities in pharmaceutical care 24th European Symposium on Clinical Pharmacy (1995)
    Springer
    Pharmacy world & science 17 (1995), S. J7 
    Details
    ISSN: 1573-739X
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01890522
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...